Danggui Sini decoction protects against oxaliplatin-induced peripheral neuropathy in rats.

Guo-Li Wei,Ji-Ping Zhu,Jie-Ge Huo,Rong Ding,Wu-Guang Lu,Yue Wang,Zhan-Cheng Gu,Zhen-Tao An

doi:10.31083/j.jin.2020.04.1154

Abstract

The effects of Danggui Sini decoction on peripheral neuropathy in oxaliplatin-induced peripheral is established. The results indicated that Danggui Sini decoction treatment significantly reduced the current amplitude of dorsal root ganglia cells undergoing agonists stimuli compared to the model-dorsal root ganglia group (P < 0.05). Danggui Sini decoction treatment significantly inhibited the inflammatory response of dorsal root ganglia cells compared to the model-dorsal root ganglia group (P < 0.05). Danggui Sini decoction treatment significantly enhanced the amounts of Nissl bodies in dorsal root ganglia cells compared to the Model-dorsal root ganglia group (P < 0.05). Danggui Sini decoction treatment improved ultra-microstructures of dorsal root ganglia cells. In conclusion, Danggui Sini decoction protected against neurotoxicity of oxaliplatin-induced peripheral neuropathy in rats by suppressing inflammatory lesions, improving ultra-microstructures, and enhancing amounts of Nissl bodies.

Highlights

Peripheral neuropathy (PN) commonly occurs post the treatment of oxaliplatin (OXAL) (Kono et al, 2015; Traina, 2017)
3.1 Danggui Sini decoction treatment reduced the current amplitude of DGR cells undergoing Agonists stimuli Patch-clamp electrophysiology results showed that the current amplitude levels of low, medium- and the high-DSD-DGR group were significantly decreased compared to the Model-GRG group (Fig. 2A, all P < 0.05)
The current amplitude levels of DSN-L, DSD-M, GSD-H-dorsal root ganglia (DRG) + capsaicin group were significantly decreased compared to the Model-DRG + capsaicin group (Fig. 2A, all P < 0.05)

Summary

Introduction

Peripheral neuropathy (PN) commonly occurs post the treatment of oxaliplatin (OXAL) (Kono et al, 2015; Traina, 2017). It is caused by diabetes, toxins, or drugs (such as chemotherapeutic drugs), burns. For diabetic peripheral neuropathy (DPN) during the diabetes process, which occurs or develops in 47% to 91% diabetes patients (Sathya et al, 2017). For patients receiving neurotoxic chemotherapy, about 30% to 40% of whom would develop chemotherapy-induced peripheral neuropathy (CIPN) (Pike et al, 2012). The association between burns and PN has been proven to occur in patients with rates ranging from 2% to 52%, according to different investigations (Strong et al., 2017). The other conditions that cause injury to the peripheral nervous system could cause different categories of PN (Callaghan et al, 2015)

Methods

Results

Conclusion